Intra-Cellular Therapies, Inc.

Ownership Transactions Reported by 13 Insiders

Symbol
ITCI on Nasdaq
Location
430 East 29 Th Street, New York, New York

Insiders trading volume in the past year

Intra-Cellular Therapies, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Christopher D. Alafi Director $377M May 27, 2021
Sharon Mates Chairman and CEO, Director $79.9M -$47.2M -37.1% Aug 29, 2024
Rory B. Riggs Director $8M -$337K -4.04% Jun 28, 2024
Richard A. Lerner Director $7.16M Sep 30, 2021
Joel S. Marcus Director $3.87M -$1.81M -31.8% Jun 23, 2024
Mark Neumann EVP, Chief Commercial Officer $2.72M -$6.47M -70.4% Aug 16, 2024
Sanjeev Narula Executive Vice President & CFO $2.4M Aug 12, 2024
Suresh K. Durgam EVP, Chief Medical Officer $1.82M -$7.15M -79.8% Mar 7, 2024
Robert L. Van Nostrand Director $777K -$2.98M -79.3% Jun 28, 2024
Michael Halstead EVP and General Counsel $537K -$8.73M -94.2% Mar 7, 2024
Lawrence J. Hineline SVP of Finance, CFO $372K -$3.21M -89.6% Mar 7, 2024
Eduardo Rene Salas Director $118K Jun 23, 2024
Michael Rawlins Director Jun 9, 2022

Recent Insider Transactions by Companies or Individuals for Intra-Cellular Therapies, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.